GU Cancers Symposium 2014 - Multicenter sequential phase II study of flavopiridol plus oxaliplatin (alvocidib) with or without 5-FU and leucovorin for patients with refractory germ cell tumors including late relapse - Session Highlights

SAN FRANCISCO, CA USA (UroToday.com) - In this study, previously treated patients with progressive germ cell tumors (GCT) were eligible if they had not received or were not candidates for high-dose chemotherapy (HDCT).

Treatment was every 2 weeks in 6-week cycles, and the primary endpoint was response rate. Patients on arm one received flavopiridol 70mg/m2 plus oxaliplatin 85mg/m2, and patients in arm 2 (flavopiridol + FOLFOX) tested identical doses of flavopiridol and oxaliplatin plus 5-FU (400mg/m2 bolus, then 1800mg/m2 over 48 hours) and leucovorin (LV) 400mg/m2.

Agucancerssympalt thumb total of 36 patients (7 arm 1, 29 arm 2) were enrolled in the study, and of those, 33 had non-seminoma. Twenty -even patients had primary testis and 7 had primary mediastinum tumors. Twenty-two patients had received prior HDCT and 13 had LR (> 2 years), including 2 on arm 1 and 11 on arm 2. Since there was no response in arm 1 (0/7 patients), this arm was closed early. Of 25 evaluable patients on arm 1, 6 achieved a PR, 9 had SD, and 10 had PD. Five out of 10 evaluable LR patients on arm 1 had a PR, including one pathologic CR, one PR-negative markers who received radiation (RT) to a residual bone metastasis, and 1 PR-positive markers who received RT to a residual nodal mass. These 3 patients remain disease-free ≥ 19 months post-chemotherapy and ≥ 17months post-RT or surgery. Median progression-free survival and overall survival were 2.3 months and 7.3 months for all patients, respectively, and 3.2 months and 11.2 months for patients in arm 2.

The important take-home point of this phase 2 study is that, although neither arm met the hypothesized endpoint, flavopiridol plus FOLFOX was particularly active in later relapse patients, with approximately a 50% overall RR. Further studies are certainly needed to evaluate the use of FOLFOX, with or without flavopiridol, in late-relapse patients.

Highlights of a presentation by Darren Richard Feldman at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Memorial Sloan Kettering Cancer Center, New York, NY USA

Written by Reza Mehrazin, MD, medical writer for UroToday.com


View Full 2014 GU Cancers Symposium Coverage

 

 

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Virtual Annual Meeting / Nov 13-14
  • 2020 Annual Virtual Meeting / Oct 17
  • 2020 Annual Congress / October 10 - 11
  • 2020 Annual Meeting / October 1-3
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland